预约演示

更新于：2025-05-07

APOE

更新于：2025-05-07

基本信息

别名

AD2、Alzheimer disease 2 (APOE*E4-associated, late onset)、Apo-E

+ [3]

简介

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:2762297, PubMed:6860692, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:1911868, PubMed:6860692). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:12950167, PubMed:1530612, PubMed:1917954, PubMed:20030366, PubMed:20303980, PubMed:2063194, PubMed:2762297, PubMed:7635945, PubMed:7768901, PubMed:8756331, PubMed:8939961). Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:23676495, PubMed:7635945, PubMed:9395455, PubMed:9488694). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:23676495, PubMed:29516132, PubMed:9395455). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:1917954, PubMed:2762297, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:14754908, PubMed:23620513, PubMed:9395455). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:25173806, PubMed:8939961). APOE is also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). Binds to the immune cell receptor LILRB4 (PubMed:30333625). APOE may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074). (Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434).

关联

项与 APOE 相关的药物

Abequolixron

靶点

APOE x LXR x NR1H2

作用机制

APOE激动剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

LX-1001

靶点

ApoE2

作用机制

ApoE2调节剂

在研机构

Lexeo Therapeutics, Inc.

原研机构

Weill Cornell Medicine

在研适应症

2型阿尔茨海默病

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

TML-6

靶点

APOE x APP x NF-κB x mTOR

作用机制

APOE激动剂 [+4]

在研机构

美力龄生医股份有限公司 [+1]

原研机构

美力龄生医股份有限公司

在研适应症

阿尔茨海默症

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

项与 APOE 相关的临床试验

NCT06562114

/ Recruiting临床1期

A Phase 1, Safety, Tolerability, Single-ascending Dose, Multiple-ascending Dose, Food Effect, and Pharmacokinetic Study of TML-6 in Healthy Volunteers

The purpose of this study is to evaluate the safety, tolerability, single-ascending dose (SAD), multiple-ascending dose (MAD), food effect, and pharmacokinetic (PK) Study of TML-6.

开始日期2024-07-11

申办/合作机构

美力龄生医股份有限公司

NCT05911308

/ Terminated临床1期IIT

A Pilot Window of Opportunity Study Evaluating Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy Followed by Evaluation of Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy and Abequolixron (RGX-104) in Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) is one of the deadliest types of cancer. In lung cancer patients with a tumor that can be removed by surgery, adjuvant chemotherapy increases survival. Neoadjuvant therapy may have advantages such as, it may be more tolerable prior to surgery, earlier treatment may be more efficacious, and it can provide an indication of treatment response. Neoadjuvant treatment can provide pre- and post-treatment specimens for correlative analysis to better understand mechanisms of action and resistance.
This pilot study will investigate the effects of neoadjuvant durvalumab plus platinum doublet chemotherapy and neoadjuvant durvalumab plus platinum doublet chemotherapy in combination with abequolixron (RGX-104), an LXR/ApoE agonist, in subjects with NSCLC who are scheduled to undergo surgical resection as part of their standard of care.
The purpose of this study is to study how well using a combination of durvalumab, platinum doublet chemotherapy (carboplatin/abraxane or carboplatin/pemetrexed), and abequolixron treats non-small cell lung cancer before surgery. Durvalumab (a type of immunotherapy) and platinum doublet chemotherapy are drugs that are individually approved for use during the treatment of cancer. FDA (Food and Drug Administration) has not approved the combined use of these drugs in treating non-small cell lung cancer. Abequolixron is not FDA approved for the treatment of cancer.

开始日期2024-04-01

申办/合作机构

UNC Lineberger Comprehensive Cancer Center

[+2]

NCT05400330

/ Enrolling by invitation临床1期

Long-Term Follow-Up to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease

The primary purpose of this long-term follow-up study is to assess the long-term safety profile of APOE4 homozygote participants who were administered gene therapy (LX1001) for the treatment of Alzheimer's disease in Study LX100101. A secondary objective is to assess the biomarker as shown by the conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4. Additional secondary outcomes include amyloid PET scan, CSF markers (including Aβ42, Aβ42/Aβ40 ratio T--tau, and P-tau), and quantitative MRI (and other biomarkers that may be informative for this therapeutic approach). Other secondary objectives include instruments to assess cognitive and clinical AD and to evaluate if treatment with AAVrh.10hAPOE2 improves brain tau pathology with tau PET scan (LX1001-01 Cohorts 3 and 4 only).

开始日期2023-05-08

申办/合作机构

Lexeo Therapeutics, Inc.

100 项与 APOE 相关的临床结果

登录后查看更多信息

100 项与 APOE 相关的转化医学

登录后查看更多信息

0 项与 APOE 相关的专利（医药）

登录后查看更多信息

32,864

项与 APOE 相关的文献（医药）

2025-12-31·Annals of Medicine

Deciphering the role of APOE in cerebral amyloid angiopathy: from genetic insights to therapeutic horizons

Review

作者: Zhang, Nan ; Li, Hanyu ; Hu, Hantian ; Wang, Qi ; Wan, Siqi ; Hu, Yuetao

Cerebral amyloid angiopathy (CAA), characterized by the deposition of amyloid-β (Aβ) peptides in the walls of medium and small vessels of the brain and leptomeninges, is a major cause of lobar hemorrhage in elderly individuals. Among the genetic risk factors for CAA that continue to be recognized, the apolipoprotein E (APOE) gene is the most significant and prevalent, as its variants have been implicated in more than half of all patients with CAA. While the presence of the APOE ε4 allele markedly increases the risk of CAA, the ε2 allele confers a protective effect relative to the common ε3 allele. These allelic variants encode three APOE isoforms that differ at two amino acid positions. The primary physiological role of APOE is to mediate lipid transport in the brain and periphery; however, it has also been shown to be involved in a wide array of biological functions, particularly those involving Aβ, in which it plays a known role in processing, production, aggregation, and clearance. The challenges posed by the reliance on postmortem histological analyses and the current absence of an effective intervention underscore the urgency for innovative APOE-targeted strategies for diagnosing CAA. This review not only deepens our understanding of the impact of APOE on the pathogenesis of CAA but can also help guide the exploration of targeted therapies, inspiring further research into the therapeutic potential of APOE.

2025-12-31·Pharmaceutical Biology

Yiqi Wenyang decoction protects against the development of atherosclerosis by inhibiting vascular inflammation

Article

作者: Jiang, Weimin ; Yan, Xingqun ; Gu, Ping ; Zhu, Yao ; Sun, Lingling ; Shiu, Chiwen ; Zhang, Han ; Hua, Shuang ; Huang, Zhe ; Zhang, Shujie

CONTEXTVascular inflammation is a key process in the pathogenesis of atherosclerosis, which is regulated by NF-κB pathway. Yiqi Wenyang decoction (YQWY), a Traditional Chinese medicine (TCM) formula, has anti-inflammatory properties and may inhibit this pathway, potentially offering anti-atherosclerotic effects.OBJECTIVEThe purpose of this study is to investigate the effects of YQWY on atherosclerosis and the underlying mechanism. Materials and methods: ApoE^-/- mice were fed a Western diet and administered with YQWY (low or high dose), atorvastatin, or vehicle for 13 weeks. The size of atherosclerotic plaques was assessed using ORO staining. Vascular inflammation was evaluated with IF or IHC staining. The mechanisms and signaling pathways underlying the effect of YQWY on vasculature were studied using transcriptomic analysis and were validated in vitro in endothelial cells and macrophages.RESULTSYQWY attenuated atherosclerotic plaque development which was associated with reduced vascular inflammation as demonstrated by transcriptomic analysis of aorta. This was verified by reduced expression of proinflammatory chemokines, adhesion molecules, and inflammatory cytokines in aortas from YQWY-treated mice at both mRNA and protein levels. Mechanistically, YQWY suppressed NF-κB activation in endothelial cells and, to a lesser extent, macrophages possibly.DISCUSSION AND CONCLUSIONSYQWY protects against vascular inflammation and atherosclerosis by suppressing NF-κB pathway, suggesting the potential of YQWY and its active ingredients as novel anti-atherosclerotic therapeutics.

2025-12-31·Gut Microbes

Gut microbiota and derived metabolites mediate obstructive sleep apnea induced atherosclerosis

Article

作者: Meadows, Jason ; Allaband, Celeste ; Zuffa, Simone ; Zhou, Dan ; Poulsen, Orit ; Haddad, Gabriel G ; Dorrestein, Pieter C ; Xue, Jin ; Knight, Rob

Obstructive sleep apnea (OSA) is characterized by intermittent hypoxia/hypercapnia (IHC), affects predominantly obese individuals, and increases atherosclerosis risk. Since we and others have implicated gut microbiota and metabolites in atherogenesis, we dissected their contributions to OSA-induced atherosclerosis. Atherosclerotic lesions were compared between conventionally-reared specific pathogen free (SPF) and germ-free (GF) Apoe^-/- mice following a high fat high cholesterol diet (HFHC), with and without IHC conditions. The fecal microbiota and metabolome were profiled using 16S rRNA gene amplicon sequencing and untargeted tandem mass spectrometry (LC-MS/MS) respectively. Phenotypic data showed that HFHC significantly increased atherosclerosis as compared to regular chow (RC) in both aorta and pulmonary artery (PA) of SPF mice. IHC exacerbated lesions in addition to HFHC. Differential abundance analysis of gut microbiota identified an enrichment of Akkermansiaceae and a depletion of Muribaculaceae (formerly S24-7) family members in the HFHC-IHC group. LC-MS/MS showed a dysregulation of bile acid profiles with taurocholic acid, taurodeoxycholic acid, and 12-ketodeoxycholic acid enriched in the HFHC-IHC group, long-chain N-acyl amides, and phosphatidylcholines. Interestingly, GF Apoe^-/- mice markedly reduced atherosclerotic formation relative to SPF Apoe^-/- mice in the aorta under HFHC/IHC conditions. In contrast, microbial colonization did not show a significant impact on the atherosclerotic progression in PA. In summary, this research demonstrated that (1) IHC acts cooperatively with HFHC to induce atherosclerosis; (2) gut microbiota modulate atherogenesis, induced by HFHC/IHC, in the aorta not in PA; (3) different analytical methods suggest that a specific imbalance between Akkermansiaceae and Muribaculaceae bacterial families mediate OSA-induced atherosclerosis; and (4) derived bile acids, such as deoxycholic acid and lithocholic acid, regulate atherosclerosis in OSA. The knowledge obtained provides novel insights into the potential therapeutic approaches to prevent and treat OSA-induced atherosclerosis.

695

项与 APOE 相关的新闻（医药）

2025-05-01

·医药速览

AD新药之争，提前分出胜负！

欧洲时间4月15日，仑卡奈单抗正式获得欧盟批准上市，用于治疗经临床诊断为轻度认知障碍及轻度痴呆的早期阿尔茨海默病（AD）成人患者，且为载脂蛋白E ε4（ApoE ε4）非携带者或杂合子，并经确认存在β-淀粉样蛋白病理。此次获批，使仑卡奈单抗成为首款在欧盟获批用于治疗符合条件的早期阿尔茨海默病（early AD）患者的、针对该疾病潜在病因的药物。而20天前，欧洲药品管理局（EMA）人用药品委员会（CHMP）却以 “疗效不足以抵消安全风险” 为由，拒绝批准多奈单抗在欧盟上市。在很多人眼里，仑卡奈单抗和多奈单抗大同小异，都是针对Aβ的药物，这让EMA的拒批看起来非常无理，但实际上二者在证据的充分性和获益程度上，表现大相径庭。漫漫审批路EMA向来是全球最为保守的药物审批部门，仑卡奈单抗在欧盟的批准也是一波三折。EMA是先拒绝了仑卡奈单抗的上市申请，后经补充递交数据再次申请后，才由拒绝转为建议批准。期间多奈单抗吸取了仑卡奈单抗第一次闯关失败被拒的经验，直接放弃挑战ARIA发生率较高的ApoE ε4携带人群。但EMA依然认为，即便对于非ApoE4携带者这一小规模人群，多奈单抗的有限疗效收益仍不足以抵消其引发致命性ARIA的风险。EMA在对TRAILBLAZER – ALZ 2研究的数据进行进一步分析后，发现其对于ApoE ε4非携带者的安全性表现依然不尽如人意，ARIA事件总体发生率达到了24%，比安慰剂组的12%高出一倍，与Clarity AD研究中仑卡奈单抗在总人群中的ARIA发生率相当。那既然仑卡奈单抗没有获批全人群适应症，多奈单抗自然无法获批ApoE ε4非携带者的适应症。更为致命的是，礼来方面虽然提出了重新审查的要求，但他们似乎很难提供更多过硬的证据了。多奈单抗的治疗目标为清除大脑中的淀粉样蛋白斑块，当斑块水平评估达标后即可停药。但这个特点导致其患者的平均暴露时间差别很大，有一些患者可能在12个月内实现停药，有一些患者则可能治疗时长大大超过18个月，疗程并不明确。这导致其在长期疗效数据上的披露进度远落后于仑卡奈单抗。在EMA的意见中也指出，对于多奈单抗治疗ApoE ε4非携带早期AD患者，目前尚无长期有效性数据支持。而且，即便是现有的疗效数据，多奈单抗的获益也很并不明显。从整体数据来看，接受多奈单抗治疗的患者 iADRs 评分恶化了 10 分，而接受安慰剂治疗的患者恶化了 13 分。这表明多奈单抗虽然在一定程度上使患者的评分恶化程度稍低，但改善幅度并不显著，仅仅只有 3 分的差异。而在ApoE ε4非携带者中，接受多奈单抗治疗的患者 iADRs 评分恶化14分，接受安慰剂治疗的患者恶化 16分。也就是说，在这一特定人群中，多奈单抗与安慰剂的差值仅有2 分。这样的疗效收益绝对无法抵消安全性上的风险。靶点带来安全性差异淀粉样蛋白相关性影像异常（ARIA）是所有抗Aβ药物治疗都可能产生的副作用，因为Aβ不仅可沉积于脑实质，也可沉积于脑血管壁，导致血管壁的结构和功能异常，增加了血管的脆性和易损性。但脑实质与血管壁上的Aβ并不是同样的Aβ，血管壁上沉积的主要是Aβ40，而Aβ42才是主要参与Aβ级联反应的聚合体。所以理想的阿尔茨海默病抗体药物应该尽可能减少与Aβ40的结合度，增加与Aβ42的结合度。而多奈单抗与Aβ40的结合力度比仑卡奈单抗高，这导致理论上多奈单抗的安全性比仑卡奈单抗更差。临床研究结果表明，多奈单抗的ARIA-E和ARIA-H发生率都比仑卡奈单抗高出一倍左右，而且多奈单抗的临床试验中还出现了3例导致受试者死亡的严重ARIA事件。欧盟对抗Aβ药物态度的 “冰火两重天”，远不是安全性问题可以概括，需要综合评价药物的风险与治疗获益。由于AD 治疗需要“早期干预、长期管理” ，所以药物既要有长期疗效证据，也要能保证长期用药的安全，二者缺一不可，不能做一锤子买卖。推文用于传递知识，如因版权等有疑问，请于本文刊发30日内联系医药速览。原创内容未经授权，禁止转载至其他平台。有问题可发邮件至yong_wang@pku.edu.cn获取更多信息。©2021 医药速览保留所有权利往期链接“小小疫苗”养成记 | 医药公司管线盘点人人学懂免疫学| 人人学懂免疫学（语音版）综述文章解读 | 文献略读 | 医学科普|医药前沿笔记PROTAC技术| 抗体药物| 抗体药物偶联-ADC核酸疫苗 | CAR技术| 化学生物学温馨提示医药速览公众号目前已经有近12个交流群（好学，有趣且奔波于医药圈人才聚集于此）。进群加作者微信（yiyaoxueshu666）或者扫描公众号二维码添加作者，备注“姓名/昵称-企业/高校-具体研究领域/专业”，此群仅为科研交流群，非诚勿扰。简单操作即可星标⭐️医药速览，第一时间收到我们的推送①点击标题下方“医药速览” ②至右上角“...” ③点击“设为星标

上市批准临床结果

2025-04-30

·GlobeNewswire-Health Care

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkersNAARDEN, the Netherlands and MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will present new clinical and preclinical data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society (EAS) 93rd Congress, taking place on May 4-7, 2025 in Glasgow, UK. Late-breaker oral presentation details are as follows: Title: Fixed-Dose Combination of Obicetrapib and Ezetimibe for LDL-C Reduction: A Phase 3 Randomized TrialSession Name: Late Breaker Session: ClinicalOral Presentation Date and Time: Wednesday, May 5, 2025, 12:00-12:15 PM BST (7:00-7:15 AM ET)Location: William Harvey Hall Title: Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskSession Name: Late Breaker Session: ClinicalOral Presentation Date and Time: Wednesday, May 5, 2025, 12:15-12:30 PM BST (7:15-7:30 AM ET)Location: Will Harvey Hall Additional session details are as follows: Title: Obicetrapib Reduces Atherosclerosis and Vascular Inflammation, Mainly by Reducing Non-HDL Cholesterol, Improves Lesion Stability and Adds to the Beneficial Effects of EzetimibeSession Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and OutcomesPresentation Date and Time: Monday, May 5, 2025, 1:58-2:05 PM BST (8:58-9:05 AM ET)Location: Station 7 Title: Obicetrapib Alone and in Combination with Ezetimibe Increases Reverse Cholesterol Transport and Does Not Affect VLDL ProductionSession Name: SaaG Session: Emerging Lipid-Lowering Strategies: Mechanisms, Pre-clinical Studies and OutcomesPresentation Date and Time: Monday, May 5, 2025, 2:05-2:12 PM BST (9:05-9:12 AM ET)Location: Station 7 Title: Low-Dose Obicetrapib Significantly Increases Concentrations of Lipophilic Antioxidants, ApoE, and S1P in HDL SubfractionsSession Name: SaaG Session: Lipid Lowering Therapies and Advances in Vascular TherapeuticsPresentation Date and Time: Monday, May 5, 2025, 2:19-2:26 PM BST (9:19-9:26 AM ET)Location: Station 4 Title: Obicetrapib Significantly Increases Plasma and High-Density Lipoprotein (HDL) Levels of Lipophilic AntioxidantsSession Name: SaaG Session: Lipoprotein Dynamics: HDL to RemnantsPresentation Date and Time: Monday, May 5, 2025, 3:17-3:24 PM BST (10:17-10:24 AM ET)Location: Station 3 Title: Efficacy and Safety of Combination Obicetrapib with Moderate-Dose StatinsSession Name: Poster Networking SessionsPresentation Date and Time: Monday, May 5 & Tuesday, May 6, 2025, 5:20 - 6:50 PM BST (12:17-1:24 PM ET)Location: Poster Board #246, Exhibition Hall Title: Safety and Efficacy of Cholesteryl Ester Transfer Protein Inhibition: From Genetics to Outcome TrialsSession Name: Workshop: New risk factors for atherosclerotic diseasePresentation Date and Time: Wednesday, May 7, 2025, 12:20 -12:30 PM BST (7:17-8:24 AM ET)Location: James Black Hall About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Matthew PhilippeP: 1-917-882-7512matthew.philippe@newamsterdampharma.com Media Contact Spectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@spectrumscience.com Investor Contact Precision AQ on behalf of NewAmsterdamAustin MurtaghP: 1-212-698-8696austin.murtagh@precisionaq.com

临床3期

2025-04-29

·PRNewswire

ApoE4 Alzheimer's Alliance Launches to Advocate for ApoE4 Patients, Urges FDA Action

WASHINGTON, April 29, 2025 /PRNewswire/ -- The ApoE4 Alzheimer's Alliance, a new patient advocacy organization, is launching to amplify the voices of individuals with the ApoE4 gene and work with organizations to enact policy priorities. The Alliance will advocate for the unique needs of this community before U.S. policymakers and the U.S. Food and Drug Administration (FDA), pushing for accelerated progress toward innovative treatments and supportive policies. Continue Reading View PDF Individuals with the ApoE4 gene are at a significantly higher risk of developing Alzheimer's disease, often experiencing earlier onset, rapid disease progression, and limited therapeutic options. Despite this heightened risk, ApoE4 patients remain underrepresented in research and underserved in clinical care. The ApoE4 Alzheimer's Alliance is committed to addressing these disparities through: Advocacy: Lobbying for increased federal funding for ApoE4-specific research, urging policymakers and the FDA to prioritize ApoE4-targeted therapies, and promoting equitable access to diagnostic testing and care. Education: Raising awareness about the heightened risk for ApoE4 carriers, providing resources and support to patients and caregivers, and engaging with medical professionals to improve ApoE4-specific care protocols. Partnership Building: Collaborating with pharmaceutical companies to advance ApoE4-targeted drug development, partnering with academic institutions to fund cutting-edge research and to amplify lived experiences and policy priorities. Patient Storytelling: Highlighting real-world experiences of APOE4 patients and caregivers to humanize the challenges and drive urgency for action. In conjunction with its launch, the Alliance has sent an open letter to the FDA Commissioner, Dr. Martin A. Makary, MD, urging the agency to take specific actions to protect ApoE4 patients, particularly considering recent research highlighting the risks associated with current Alzheimer's treatments for this population. Key points from the letter include: Require APOE Genotyping Prior to Treatment: The Alliance calls for a regulatory mandate that all patients considering anti-amyloid antibody treatments undergo APOE genotyping to assess their individual risk profile. Mandate Full Disclosure of Genetic Risk in Clinical Trials: The letter emphasizes the need for transparency, ensuring that participants in clinical trials are informed of their APOE status. Enhance Risk Communication in Practice: The Alliance advocates for updated labeling and prescribing guidelines that explicitly outline the elevated ARIA risk in ApoE4 carriers. Support Targeted Clinical Trials: The letter urges the FDA to encourage and facilitate clinical trials that specifically address the safety and efficacy of anti-amyloid therapies in APOE4 homozygotes. "The APOE4 community faces unique challenges that demand immediate attention," said Jamie Tyrone, Board Member of the ApoE4 Alzheimer's Alliance. "Our goal is to drive meaningful change by advocating for research, access to care, and policies that address the specific needs of ApoE4 patients and their families."The ApoE4 Alzheimer's Alliance is committed to working collaboratively with all stakeholders to accelerate progress in Alzheimer's research and improve the lives of those affected by this devastating disease. About ApoE4 Alzheimer's Alliance:The ApoE4 Alzheimer's Alliance is a patient advocacy organization dedicated to representing the interests of ApoE4 Alzheimer's patients. The Alliance advocates for tailored treatment strategies, increased research funding, and equitable access to care for this high-risk population. SOURCE ApoE4 Alzheimer's Alliance WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED